



Implanet admitted to the *SRD long-seulement* Long-only Deferred Settlement Service

Bordeaux, Boston, 2 December 2015 – IMPLANET (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, announces that its shares will be admitted to the Euronext Paris SRD (*Service de Règlement Différé*, i.e. Deferred Settlement Service) from 29 December 2015, on the “*Long-seulement*” (Long-only) segment.

With a minimum daily trading volume of €100,000 over the past year, a condition for being admitted to the *SRD Long-seulement* Long-only Deferred Settlement Service, the liquidity of Implanet shares has increased significantly as a result of the substantial improvement in the Group’s fundamentals.

In practical terms, the *SRD long-seulement* will allow those with a French securities account to purchase Implanet shares on margin using the leveraged effect of deferred settlement. For the buyer, risks are thus limited to the initial size of the investment. Contrary to the standard Deferred Settlement Service, shares listed on the “*Long-only*” segment are only eligible for purchase, and are not tradable on the centralized borrowing and lending market.

Being admitted to the “*SRD Long seulement*” will make Implanet shares more attractive and will increase liquidity by providing access to a broader base of institutional and individual investors.



About IMPLANET

Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 45 staff and recorded 2014 sales of €7.0 million. For further information, please visit www.implanet.com.

Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013. IMPLANET is listed on Compartment C of the Euronext™ regulated market in Paris.

IMPLANET

Ludovic Lastennet
Directeur Général
Tél. : 05 57 99 55 55
investors@implanet.com

NewCap

Relations Investisseurs
Florent Alba
Tél. : 01 44 71 94 94
implanet@newcap.eu

NewCap

Relations Presse
Nicolas Merigeau
Tél. : 01 44 71 94 98
implanet@newcap.eu